Refine
Has Fulltext
- yes (2)
Is part of the Bibliography
- yes (2)
Document Type
- Journal article (1)
- Doctoral Thesis (1)
Keywords
- ANP (1)
- Atriales natriuretisches Hormon (1)
- Ca2+i handling (1)
- GC-A (1)
- GMPcGMP-dependent protein kinase I (1)
- Guanylatcyclase (1)
- PKG I (1)
- cardiac hypertrophy (1)
- cyclic (1)
- natriuretic peptide (1)
Institute
Aims: Cardiac hypertrophy is a common and often lethal complication of arterial hypertension. Elevation of myocyte cyclic GMP levels by local actions of endogenous atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) or by pharmacological inhibition of phosphodiesterase-5 was shown to counter-regulate pathological hypertrophy. It was suggested that cGMP-dependent protein kinase I (cGKI) mediates this protective effect, although the role in vivo is under debate. Here, we investigated whether cGKI modulates myocyte growth and/or function in the intact organism.
Methods and results: To circumvent the systemic phenotype associated with germline ablation of cGKI, we inactivated the murine cGKI gene selectively in cardiomyocytes by Cre/loxP-mediated recombination. Mice with cardiomyocyte-restricted cGKI deletion exhibited unaltered cardiac morphology and function under resting conditions. Also, cardiac hypertrophic and contractile responses to β-adrenoreceptor stimulation by isoprenaline (at 40 mg/kg/day during 1 week) were unaltered. However, angiotensin II (Ang II, at 1000 ng/kg/min for 2 weeks) or transverse aortic constriction (for 3 weeks) provoked dilated cardiomyopathy with marked deterioration of cardiac function. This was accompanied by diminished expression of the \([Ca^{2+}]_i\)-regulating proteins SERCA2a and phospholamban (PLB) and a reduction in PLB phosphorylation at Ser16, the specific target site for cGKI, resulting in altered myocyte \(Ca^{2+}_i\) homeostasis. In isolated adult myocytes, CNP, but not ANP, stimulated PLB phosphorylation, \(Ca^{2+}_i\)-handling, and contractility via cGKI.
Conclusion: These results indicate that the loss of cGKI in cardiac myocytes compromises the hypertrophic program to pathological stimulation, rendering the heart more susceptible to dysfunction. In particular, cGKI mediates stimulatory effects of CNP on myocyte \(Ca^{2+}_i\) handling and contractility.
In diesem Projektteil charakterisierten wir mittels vergleichenden Analysen an Mäusen mit konditioneller, herzspezifischer Deletion der GC-A (CM GC-A KO; (Holtwick et al., 2003; Kilic et al., 2005 und 2007)) und Kontrolltieren die zellulären Mechanismen, welche bei Dysfunktion des ANP/GC-A-Systems die Entwicklung von Herzhypertrophie begünstigen. Wir untersuchten, ob/wie ANP die kardialen Effekte von -adrenerger versus Ang II/AT1 (Gs versus Gq-mediierter) Stimulation beeinflusst. Zunächst kombinierten wir an isolierten adulten murinen Kardiomyozyten elektrophysiologische Messungen der L-Typ Ca2+ Ströme (LTCS, mittels voltage-clamp Messungen in Kooperation mit Herrn Dr. M. Kruse und Herrn Prof. O. Pongs am Zentrum für Molekulare Neurobiologie, Universität Hamburg), fluorometrische Messungen der intrazellulären Calcium-Transienten (mittels Indo-1 AM) und Messungen der Kontraktilität (Zellverkürzung, mittels edge detection). Diese ex vivo Untersuchungen zeigten, dass Isoproterenol (ISO) und Ang II die LTCS, [Ca2+]i und Kontraktilität isolierter adulter Myozyten stimulieren. Interessanterweise hemmt ANP/GC-A die Effekte von Ang II, nicht aber die Effekte von ISO. Um der Bedeutung dieser Interaktion zwischen ANP und Ang II für die Entwicklung einer pathologischen Herzhypertrophie ...